Friday, September 29, 2023


Biotechnology News Magazine

Tabula Rasa Healthcare: New Study Predicts Risks of Drug Interactions without Exposing Patients to Harm

Latest Posts

Airway Therapeutics Completes Dose Escalation in Phase 1b Trial of Zelpultide Alfa (AT-100) for Very Preterm Infants at Risk for Bronchopulmonary Dysplasia

Airway Therapeutics began recruiting patients on March 28, 2023, for daily treatment up to 7 days at the highest dose of zelpultide alfa (rhSP-D) following a Data Safety Monitoring Committee (DSMC) report of no safety concerns.

Roche introduces navify® Algorithm Suite, a digital library of medical algorithms that enhances clinical decision-making to optimise patient care

At the global HIMSS1 Conference, Roche showcases navify Algorithm Suite, a single platform offering clinicians access to medical algorithms generating insights to help improve care decisions.

PathO3Gen Solutions UVZone® Proven 99.9993% Effective Against Candida Auris: Shoes and Floors in Healthcare Facilities Should Be Addressed as Outbreak Continues

PathO3Gen Solutions’ multi-patented UVZone Shoe Sanitizing Stations, when placed in high-traffic and high-risk areas, enhance healthcare facility infection control measures, and may improve overall hospital biosafety.

Pharming announces the first commercial shipments of Joenja® (leniolisib) to patients in the U.S.

Under the terms of Pharming's 2019 exclusive license agreement with Novartis for leniolisib, the corresponding first commercial sale of Joenja® triggers a $10 million milestone payment by Pharming to Novartis.

Tabula Rasa HealthCare, Inc. (“TRHC”) (NASDAQ: TRHC), a leading healthcare technology company advancing the safe use of medication, and Regence Health Plans today announced the results of a simulation-based clinical study which demonstrates that TRHC’s MedWise® medication risk score can be used to assess drug safety without exposing real people to actual harm.

The study, published online in Clinical and Translational Science, used TRHC’s proprietary MedWise medications safety technology to virtually assess the potential risk of adverse drug events (ADEs) when adding repurposed drugs for COVID-19 treatment to the individual medications of a large-scale population. The results demonstrate that medication risk scores could be used to effectively assess drug safety before exposing patients to repurposed drugs.

“Through this innovative simulation we have demonstrated the value of our MedWise technology as part of a blueprint to assess the safety of newly prescribed repurposed drugs without exposing real patients to potential harm,” said TRHC Chairman and CEO Calvin H. Knowlton, Ph.D. “By partnering with Regence Health Plans, we have confirmed a powerful preemptive tool to identify individuals at higher risk of adverse drug events, to foresee types of potential risks, and to pin-point drugs to be monitored on an individual level.”

The simulated risk assessment examined de-identified medical information from approximately 500,000 Medicare and commercially insured Regence Health Plan members. Researchers determined each person’s baseline MedWise Risk Score™ (MRS) and simulated the addition of five drugs repurposed for COVID-19 treatment. The change in the MedWise Risk Score was used as a predictive tool to assess the risk of adverse drug events associated with repurposed drugs for COVID-19.

“Using a simulation-based approach, we are able to apply scientific data on the drugs’ mechanisms and metabolisms to determine how these drugs would alter a patient’s medication risk score—without putting the patients at risk,” said Veronique Michaud, Chief Operating Officer, TRHC Precision Pharmacotherapy Research and Development Institute. “We can use this data to identify patients at higher risk of adverse drug events from large populations. Once identified, our TRHC MedWise Advisor services can provide appropriate individual recommendations to mitigate the risk of ADEs.”

“We are very pleased to be a part of this novel simulation-based clinical study,” said Matthew Hafermann, a Regence’s Clinical Pharmacist. “The simulation strategy using a medication risk score represents an innovative approach to furthering patient safety by preemptively estimating the risk of adverse drug events.”

Latest Posts

Learn More




Our Sister Publication

Medical Device News Magazine